GLPwatch
Papers (9189)
Page 57 of 154, ranked by citation count.
- Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
- Exenatide and Sitagliptin Decrease Interleukin 1β, Matrix Metalloproteinase 9, and Nitric Oxide Synthase 2 Gene Expression But Does Not Reduce Alveolar Bone Loss in Rats With Periodontitis.
- Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis.
- The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
- Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity.
- Antidepressant activity of anti-hyperglycemic agents in experimental models: A review.
- Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty.
- B-cell translocation gene 2 positively regulates GLP-1-stimulated insulin secretion via induction of PDX-1 in pancreatic β-cells.
- A peripheral lipid sensor GPR120 remotely contributes to suppression of PGD<sub>2</sub>-microglia-provoked neuroinflammation and neurodegeneration in the mouse hippocampus.
- Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.
- A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia.
- Exendin-4 improves hepatocyte injury by decreasing proliferation through blocking NGF/TrkA in diabetic mice.
- GLP-1 and exendin-4 for imaging endocrine pancreas. A review. Labelled glucagon-like peptide-1 analogues: past, present and future.
- Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials.
- Future directions in obesity pharmacotherapy.
- Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.
- Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.
- GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
- Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
- The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome.
- Exendin-4 antagonizes Aβ1-42-induced suppression of long-term potentiation by regulating intracellular calcium homeostasis in rat hippocampal neurons.
- Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion.
- Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
- Semaglutide in Cystic Fibrosis-Related Diabetes.
- Effects of the multilayer structures on Exenatide release and bioactivity in microsphere/thermosensitive hydrogel system.
- Conditioning techniques and ischemic reperfusion injury in relation to on-pump cardiac surgery.
- Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases.
- Effects of Pluronic F127-PEG multi-gel-core on the release profile and pharmacodynamics of Exenatide loaded in PLGA microspheres.
- Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.
- Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.
- Prescription Fills for Semaglutide Products by Payment Method.
- Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
- Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
- US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events.
- Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease.
- Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype.
- Incretin-based therapies for the treatment of obesity-related diseases.
- Related expressional change of HIF-1α to the neuroprotective activity of exendin-4 in transient global ischemia.
- Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists.
- Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery.
- Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
- Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.
- Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
- Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.
- Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus.
- The glucagon-like peptide-1 analogue liraglutide promotes autophagy through the modulation of 5'-AMP-activated protein kinase in INS-1 β-cells under high glucose conditions.
- Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes.
- The Akt/FoxO1/p27 pathway mediates the proliferative action of liraglutide in β cells.
- The contribution of serotonin 5-HT2C and melanocortin-4 receptors to the satiety signaling of glucagon-like peptide 1 and liraglutide, a glucagon-like peptide 1 receptor agonist, in mice.
- GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
- Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.
- Semaglutide for the Treatment of Type 2 Diabetes Mellitus.
- Efficacy of laparoscopic sleeve gastrectomy and intensive medical management in obese patients with type 2 diabetes mellitus.
- Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.
- An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.
- Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.
- Liraglutide improves atherosclerosis by regulating long non-coding RNA RMRP/miR-128-1-5P/Gadd45g axis.
- Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.
- Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis.